Código QR (código de barras bidimensional)

Astatine-211 based radionuclide therapy: Current clinical trial landscape

Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe on...

ver descrição completa

Na minha lista:
Principais autores: Per Albertsson, Tom Bäck, Karin Bergmark, Andreas Hallqvist, Mia Johansson, Emma Aneheim, Sture Lindegren, Chiara Timperanza, Knut Smerud, Stig Palm
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2023-01-01
coleção:Frontiers in Medicine
Assuntos:
targeted alpha therapy
alpha particle
astatine-211
radionuclide
human
clinical trial
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fmed.2022.1076210/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados